Literature DB >> 32436340

In Reply.

Enrique Grande1, Javier Molina-Cerrillo2, Teresa Alonso-Gordoa2.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 32436340      PMCID： PMC7418357          DOI： 10.1634/theoncologist.2020-0336

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  8 in total

1.  Are Cyclin-Dependent Kinase 4/6 Inhibitors Without Future in Neuroendocrine Tumors?

Authors:  Sara Pusceddu; Francesca Corti; Massimo Milione; Giovanni Centonze; Natalie Prinzi; Martina Torchio; Filippo de Braud
Journal:  Oncologist       Date:  2020-06-16

Review 2.  Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment.

Authors:  Todd VanArsdale; Chris Boshoff; Kim T Arndt; Robert T Abraham
Journal:  Clin Cancer Res       Date:  2015-05-04       Impact factor: 12.531

3.  Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma.

Authors:  Jennie W Taylor; Mili Parikh; Joanna J Phillips; C David James; Annette M Molinaro; Nicholas A Butowski; Jennifer L Clarke; Nancy Ann Oberheim-Bush; Susan M Chang; Mitchel S Berger; Michael Prados
Journal:  J Neurooncol       Date:  2018-08-27       Impact factor: 4.130

4.  SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).

Authors:  Martin J Edelman; Mary W Redman; Kathy S Albain; Eric C McGary; Noman M Rafique; Daniel Petro; Saiama N Waqar; Katherine Minichiello; Jieling Miao; Vassiliki A Papadimitrakopoulou; Karen Kelly; David R Gandara; Roy S Herbst
Journal:  J Thorac Oncol       Date:  2019-07-11       Impact factor: 15.609

5.  CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.

Authors:  Angela DeMichele; Amy S Clark; Kay See Tan; Daniel F Heitjan; Kristi Gramlich; Maryann Gallagher; Priti Lal; Michael Feldman; Paul Zhang; Christopher Colameco; David Lewis; Melissa Langer; Noah Goodman; Susan Domchek; Keerthi Gogineni; Mark Rosen; Kevin Fox; Peter O'Dwyer
Journal:  Clin Cancer Res       Date:  2014-12-11       Impact factor: 12.531

6.  The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407).

Authors:  Enrique Grande; Alex Teulé; Teresa Alonso-Gordoa; Paula Jiménez-Fonseca; Marta Benavent; Jaume Capdevila; Ana Custodio; Ruth Vera; Javier Munarriz; Adelaida La Casta; Juan José Díez; Pablo Gajate; Javier Molina-Cerrillo; Ignacio Matos; Eva María Cristóbal; José C Ruffinelli; José Palacios; Rocío García-Carbonero
Journal:  Oncologist       Date:  2020-02-11

7.  FOXM1: A novel drug target in gastroenteropancreatic neuroendocrine tumors.

Authors:  Franziska Briest; Erika Berg; Irina Grass; Helma Freitag; Daniel Kaemmerer; Florentine Lewens; Friederike Christen; Ruza Arsenic; Annelore Altendorf-Hofmann; Almut Kunze; Jörg Sänger; Thomas Knösel; Britta Siegmund; Michael Hummel; Patricia Grabowski
Journal:  Oncotarget       Date:  2015-04-10

8.  Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy.

Authors:  Tracy L Rose; David D Chism; Ajjai S Alva; Allison M Deal; Susan J Maygarden; Young E Whang; Jordan Kardos; Anthony Drier; Ethan Basch; Paul A Godley; Mary W Dunn; William Y Kim; Matthew I Milowsky
Journal:  Br J Cancer       Date:  2018-10-08       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.